IPCALAB:NSE:NSE-IPCA Laboratories Limited (INR)

COMMON STOCK | Drug Manufacturers - Specialty & Generic |

Last Closing

USD 1736.05

Change

+17.05 (+0.99)%

Market Cap

USD 421.90B

Volume

0.43M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Ipca Laboratories Limited, a pharmaceutical company, manufactures and markets formulations and active pharmaceutical ingredients (APIs) for various therapeutic segments in India, Europe, Africa, the Americas, Asia, CIS, and Australasia. It offers APIs in therapeutic areas of anti-hypertensive, anti-malarial, diuretic, DMARD, and anthelmintic. The company also provides generic and branded formulations in the therapeutic segments, including allergy, anti-neoplastic/cancer drugs, anti-arthritic, anti-epileptic, anti-hypertensive, cardiology, diabetes, dermatology, diabetology, emollients/protectives, fever, gastroenterology, hematology, helminthics, hepatoprotectives, immunosuppressant, infectious diseases, malaria, neurology, neuropathic pain, and NSAIDs, as well as nutraceuticals, ophthalmology, oral anti diabetes drug, orthopedics, probiotics, psychiatry, respiratory, rheumatology, and urology. It also exports its products worldwide. The company was incorporated in 1949 and is based in Mumbai, India.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-01-07 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
DIVISLAB:NSE Divi's Laboratories Limited

+16.30 (+0.28%)

USD 1,561.24B
MANKIND:NSE Mankind Pharma Ltd

+35.15 (+1.22%)

USD 1,185.39B
DRREDDY:NSE Dr. Reddy's Laboratories Limit..

+1.20 (+0.09%)

USD 1,157.53B
TORNTPHARM:NSE Torrent Pharmaceuticals Limite..

+41.15 (+1.22%)

USD 1,152.44B
LUPIN:NSE Lupin Limited

-2.65 (-0.11%)

USD 1,016.49B
ZYDUSLIFE:NSE Zydus Lifesciences Limited

+39.40 (+4.10%)

USD 978.76B
AUROPHARMA:NSE Aurobindo Pharma Limited

-15.30 (-1.17%)

USD 737.59B
ALKEM:NSE Alkem Laboratories Limited

+35.80 (+0.65%)

USD 665.89B
GLENMARK:NSE Glenmark Pharmaceuticals Limit..

+18.30 (+1.13%)

USD 447.54B
AJANTPHARM:NSE Ajanta Pharma Limited

+51.00 (+1.73%)

USD 380.23B

ETFs Containing IPCALAB:NSE

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 2.55% 83% B 85% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 2.55% 83% B 85% B
Trailing 12 Months  
Capital Gain 57.18% 78% C+ 82% B
Dividend Return 0.36% 33% F 30% F
Total Return 57.54% 78% C+ 82% B
Trailing 5 Years  
Capital Gain 190.32% 41% F 50% F
Dividend Return 3.43% 29% F 24% F
Total Return 193.75% 41% F 49% F
Average Annual (5 Year Horizon)  
Capital Gain 10.72% 16% F 19% F
Dividend Return 11.09% 15% F 19% F
Total Return 0.37% 32% F 33% F
Risk Return Profile  
Volatility (Standard Deviation) 34.79% 78% C+ 71% C-
Risk Adjusted Return 31.88% 20% F 18% F
Market Capitalization 421.90B 88% B+ 90% A-

Annual Financials (INR)

Quarterly Financials (INR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

Superior Dividend Growth

This stock has shown top quartile dividend growth in the previous 5 years compared to its sector

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Poor return on assets

The company management has delivered below median return on assets in the most recent 4 quarters compared to its peers.

Poor return on equity

The company management has delivered below median return on equity in the most recent 4 quarters compared to its peers.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector